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INTRODUCTION                                                                
Ischemic heart disease and cerebrovascular disease are the leading 
causes of death and account for about 43% and 33%, of all 16,7 million 
cardiovascular deaths worldwide, respectively. Of the 20 million 
survivors of heart attacks and strokes, a signifi cant proportion requires 
costly care(1). In anticipation of this increase in costs, there is an ongoing 
shift from treatment towards early detection and even prevention of 
cardiovascular pathology. Individual variability in response to disease or 
treatment stresses the need for imaging tools which are capable of 
early detection and therapy monitoring. Molecular imaging is emerging 
as one of the technologies that will be able to fulfi l these needs(2, 3). 
Here we review the concept and potential of molecular imaging in the 
cardiology clinic. This will be illustrated by examples of promising 
technologies in imaging of cell death in the heart and atherosclerosis 
that have entered the clinical trial stage. 
THE CONCEPT OF MOLECULAR IMAGING                    
Molecular imaging can be defi ned as the in vivo characterization and 
measurement of biological processes at the cellular and molecular level 
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within living organisms(4). It has recently been observed with increased 
interest in cardiovascular disease, as conventional imaging is effective, 
but lacks the capability of diagnosis of the early stage of pathologic 
processes. Molecular imaging technology has shown to have potential 
to visualize processes in a pre-disease stage and monitor early 
therapeutic effects (Figure 1). Finally, if imaging technology could be 
capable of visualizing the effi cacy of existing therapeutics and novel 
ones such as gene delivery, this could represent a great advance in 
personalized treatment of patients.
The development of molecular imaging tools is a challenging process. 
First, clinically relevant targets need to be found and analyzed to what 
extent they represent an ongoing disease-related cellular or molecular 
process of interest. Subsequently, a suitable probe needs to be 
developed, along with an appropriate tracer for in vivo application, 
using effi cient organ and intracellular targeting and amplifi cation 
strategies. Finally, evaluation of the probe in vitro and in vivo is necessary 
before it can be advanced into clinical trials. In Figure 2 the development 
of molecular imaging tools is explained in more detail.
Some of these targets have been identifi ed for imaging of molecular 
and cellular processes that refl ect important pathophysiological 
processes in cardiovascular disease. Several interesting targets have 
been clinically tested in atherosclerosis, in particular detection of the 
plaque that is vulnerable to rupture(5), and imaging of thrombi(6). 
Furthermore, cell death has been visualized in patients with myocardial 
infarction,(7, 8) heart failure(9) and also in oncology,(10, 11) another important 
fi eld for molecular imaging. 
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The ability to visualize morphology and function 
of the heart plays a central role in cardiology practice today. 
However, clinical tools to diagnose processes in an early phase on a 
molecular level in order to prevent dysmorphy or dysfunction are 
still lacking. There is a need for early diagnosis of molecular processes 
on a pre-disease level and the ability to monitor existing and novel 
treatments enabling personalized medicine. Molecular imaging is 
emerging in research and early clinical trials as a very promising 
approach in diagnosis and monitoring of heart disease. In this review 
we aim to discuss the potential of molecular imaging in cardiovascular 
disease.
ABSTRACT
FIGURE 1: Conventional versus Molecular imaging
Molecular imaging requires a shift from imaging anatomical and physiological changes 
towards detection of molecular changes underlying the disease, with the ability to 
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The main modalities that are being used for molecular imaging in 
cardiovascular disease are PET (positron emission tomography) and 
SPECT (single photon emission computed tomography), magnetic 
resonance (MR), ultrasound (US) and near-infrared fl uorescence 
(NIRF). Most of these tools are used preclinically; however, some have 
managed to embark in the clinical setting.
Nuclear medicine has the longest history of molecular imaging, with 
fi rst specifi c targets being imaged over 30 years ago. It consists of 
molecular probes, labelled with a short-lived positron- or gamma 
(photon) emitting radionuclide, which are injected into the human 
body. Subsequently, its distribution is analyzed with PET or SPECT to 
understand the interaction between the radiolabeled molecular probe 
and its target molecules in vivo(12). Currently, the most widely used PET 
radiopharmaceutical is the glucose analog 18F-FDG (fl uoro-2-deoxy-D-
glucose). 18F-FDG has been used extensively to estimate glucose 
utilization in heart and brain. 18F-FDG stays inside the cells, since 
18F-FDG lacks the 2-oxygen in glucose, disabling glycolysis before 
radioactive decay. Therefore 18F-FDG gives a good refl ection of the 
distribution of glucose uptake in the body, and allows for imaging 
cells with high metabolic rate. In general, PET facilities must have 
cyclotrons to make ultra-short half-lived radionuclides (F-18: 108 min, 
C-11: 20 min, N-13: 10 min, O-15: 2 min). Like PET, SPECT is a 
quantitative, radionuclide-based imaging method, although it is up to 
two orders of magnitude less sensitive than PET. It employs longer-lived 
radionuclides, often requiring chelation chemistry for appropriate 
linking to the targeting agent. The most common gamma emitters used 
are technetium-99m, iodine-123, indium-111, and iodine-131 with 
physical half-lives of 6 hrs, 13 hrs, 3 days and 8 days, respectively.
Another good candidate for molecular imaging is magnetic resonance 
imaging (MRI)(13). Although the sensitivity is relatively low when 
compared with PET or SPECT, MRI allows high-resolution anatomical 
and functional images of the cardiovascular system. The detection of 
events at the molecular level, however, usually requires high sensitivity. 
In response to the inadequate sensitivity of gadolinium chelates, novel 
MR contrast agents have been developed with signifi cantly higher 
relaxivities(14). These include paramagnetic gadolinium-containing 
liposomes and superparamagnetic iron oxide nanoparticles(15).
Also in the fi eld of ultrasound, targeted microbubbles or other 
acoustically active nanoparticles are being used for molecular 
imaging(16, 17). Microbubbles are injected and targeted to the diseased 
tissue where they produce a detectable acoustic signal. Targeting of the 
bubbles is achieved by conjugating ligands to the microbubble surface. 
As the size of microbubbles is relatively large (1-2 μm), these contrast 
agents cannot leave the intravascular space,(17) unless the vasculature in 
the target organ becomes leaky(18). Consequently, molecular imaging of 
contrast ultrasound has involved mainly molecular changes within the 
vascular compartment. Targeted contrast ultrasound has therefore 
been applied in angiogenesis,(19, 20) vascular infl ammation(21, 22) and 
thrombus formation(23).
Deﬁ ning a problem: In developing a 
clinical molecular imaging tool, a clinical 
problem must be deﬁ ned that is relevant 
(e.g. atherosclerosis) and is represented by 
an ongoing cellular or molecular process 
(e.g. plaque inﬂ ammation). Target ﬁ nding 
techniques and subsequent selection are 
essential elements in this process. In 
addition, the target has to follow certain 
requirements, such as the abundance of 
binding sites (e.g. macrophages) in the 
(patho)physiologic process, and minimal 
uptake in adjacent tissues. 
Clinical
1. Find target 2. Development & selection probe 3. Choose tracer 4. Implement
FIGURE 2: Molecular Imaging: from target ﬁ nding to visualization
Selection and development of a 
targeting probe: one must design/
ﬁ nd or produce a probe, for example a 
peptide or a protein, which binds the target 
of interest. The probe’s biodistribution 
is of critical importance. Ideally, the 
probe should be excreted by the body 
in a way that maximizes circulation and 
targeting time. However, clearance of the 
probe should be rapid enough to allow 
for sufﬁ cient contrast between the target 
tissue (e.g. the vulnerable plaque) and the 
blood pool.
Selecting a sensitive and clinically 
applicable tracer: In order to visualize 
a targeting probe, it needs to be linked 
to a contrast agent or tracer. A whole 
range of contrast agents and tracers has 
been developed, the most promising 
being radioisotopes for SPECT or 
PET, paramagnetic particles for MR, 
microspheres for US or ﬂ uorescent optical 
probes for NIRF.
Implementation of the molecular 
imaging tool: After in vitro validation, 
in vivo studies need to be performed to 
validate the use of the novel molecular 
imaging probe in preclinical models 
of disease. Visualization, correlation of 
localization and extent of uptake to the 
ongoing cellular or molecular process is 












Finally, near infrared fl uorescence (NIRF) has emerged as one of the 
most sensitive applications that is widely applied in small animal research. 
The main restriction of using NIRF is the limited penetration depth(24, 25). 
Despite this limitation, NIRF imaging may become useful in the 
detection of superfi cial signal in tissues such as the breast and the 
carotid artery. In addition, a promising approach of NIRF is fi beroptical 
imaging to characterize vulnerable components of atheroma in the 
cath lab(26).
The abovementioned molecular imaging tools have been listed in an 
overview (Table 1) to provide information on the spatial and temporal 
resolution, sensitivity, depth and dosing of each modality. The combination 
of molecular imaging tools with existing anatomical modalities, such as 
computed tomography (e.g. PET/SPECT-CT) and expected in the 
future, magnetic resonance imaging (e.g. PET-MR), enables localization 
of the uptake and improved quantifi cation, specifi city and sensitivity.
CLINICAL MOLECULAR IMAGING IN                            
CARDIOVASCULAR DISEASE
Imaging of cell death
Programmed cell death plays a crucial role in the pathogenesis of 
cardiovascular disease. A noninvasive imaging technique capable of 
localizing and quantifying cell death would permit assessment of disease 
progression or regression and similarly defi ne the effi cacy of therapy 
designed to inhibit or induce cell death. Necrosis and apoptosis are two 
distinct types of cell death which are hallmarks of injury after myocardial 
infarction(27, 28). Necrosis occurs after exogenous insults such as ischemic, 
or infl ammatory injury, and manifests itself by cellular swelling and 
rupture, disintegration of subcellular organelles, and their release of 
factors to extracellular vicinity that incites infl ammatory response(27). In 
contrast, apoptosis occurs by activation of a suicide program that leads 
to contractile protein fragmentation and condensation, along with 
DNA fragmentation and chromatin condensation; the cell shrinks and 
forms small apoptotic bodies, which are cleared without disruption of 
surrounding tissue architecture or induction of infl ammation(27). It has 
been traditionally believed that ischemia is associated with necrotic cell 
death. Recently it has been demonstrated that ischemic cell damage 
initiates the cascade of the apoptotic cell death program, which is an 
energy-requiring process in contrast to necrosis. As the energy 
production ceases in ischemia, a large proportion of the apoptotic cells 
die by the passive process of secondary necrosis.
Apoptosis leads to even redistribution of phospholipids across the lipid 
bilayer, with abundant expression of phosphatidylserine (PS) on the 
outer surface of the cell membrane(29, 30). Annexin A5 (Anx A5), an 
endogenous human protein, has high affi nity for exteriorized PS,(31, 32) 
and has been employed for SPECT imaging following intravenous 
injection after labelling with technetium-99m. The fi rst clinical use of 
technetium-99m labelled Annexin A5 has been to visualize cell death in 
patients with acute myocardial infarction(7). In this study, the Anx A5 
SPECT scan showed uptake that was clearly confi ned to the region of 
perfusion loss as demonstrated by 201thallium perfusion imaging (see 
Figure 3A). Based on earlier studies in mice, the explanation of Anx A5 
positivity in the myocardial region is likely to refl ect the aggregate of cell 
death, both necrosis as well as apoptosis(7).
In a recent study, Annexin A5 imaging has also been performed in 
9 patients with non-ischemic cardiomyopathy and advanced heart 
failure(9). Of the nine patients, fi ve showed Annexin A5 uptake in the 
left ventricular myocardium, without uptake in the right ventricle 
(Figure 3B). Uptake was found in focal regions in the myocardium in 
three patients, whereas one patient showed diffuse cardiac uptake of 
the technetium-99m labeled Annexin. Myocardial perfusion was 
essentially normal in the patients and did not match the areas of 
Annexin A5 uptake, contrasting with the infarction perfusion defect and 
uptake. These four patients had dilated cardiomyopathy (DCM) and 
had recently experienced worsening of heart failure in the last 
3 months. The fi fth patient had a myosin gene mutation and 
demonstrated a positive, diffuse uptake explained by a substantial 
decrease in LVEF in the past 6 months. Imaging cell death in heart 
failure may be used to monitor and compare therapeutic interventions 
aimed at reducing the degree or rate of development of DCM.
The presence of cardiac masses poses a diagnostic problem, since 
biopsies are associated with a high complication rate. Malignant tumors 
are characterized by an increased mitotic cell count as well as the rate 
of apoptosis, as compared to benign tumors(33). In an early clinical 
report, SPECT imaging of an intracardiac sarcoma was performed in 
a patient using 99mTc-Anx A5 along with a thallium-201 perfusion 
scintigram(11). Molecular imaging using Anx A5 might therefore 
distinguish between benign and malignant lesions and could provide 
prognostic information noninvasively and determine the strategy in the 
individual patient.
Imaging the unstable atherosclerotic plaque
Most of the acute coronary syndromes are thought to be the result of 
thrombosis of the coronary artery(34). The etiology of thrombosis is 
three-fold: plaque rupture (55-60% of cases), erosion (30-35%) and 
TABLE 1:  Characteristics of imaging modalities
CT 50–200 μm No limit min – N/A
Ultrasound 50–500 μm mm-cm sec-min – μg-mg
MRI 25–100 μm No limit min-hrs 10−3-10−5 μg-mg
Nuclear     
PET 1–2 mm No limit 10 s-min 10−11-10−12 ng
SPECT 0.5–1.5 mm No limit min 10−10-10−11 ng
Optical     
Bioluminescence 3–5 mm 1–2 mm sec-min 10−15-10−17 μg-mg
Fluorescence 2–3 mm <1 mm sec-min 10−9-10−12 μg-mg
Modality Spatial Depth Temporal  Sensitivity [Molecular
 resolution  resolution (mol/L) probe]
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A: Myocardial infarction imaging - Acute 
anteroseptal infarction in patient visualized with 
99mTc-labelled Anx A5. The image on the left shows 
increased 99mTc-Annexin-A5 uptake in the anteroseptal 
region 22 hours after reperfusion (L=liver uptake). The 
image on the right (perfusion scintigraphy 6–8 weeks 
after discharge) shows an irreversible perfusion 
defect which coincides with the area of increased 
99mTc-Annexin-A5 uptake (arrow). Anx A5 positivity 
likely reﬂ ects the aggregate of cell death after 
myocardial infarction. Modiﬁ ed from original ﬁ gure 
by Hofstra et al. Lancet 2004(7).
B: Heart Failure imaging - Long axis images of dual isotope imaging 
in a patient with dilated cardiomyopathy (DCM) using 201Tl and 99mTc-
Annexin A5 for imaging the left ventricle and Annexin A5 uptake, 
respectively. Images show DCM patient with rapid worsening of LV function, 
showing focal uptake in the apex and lateral wall in bottom panels, and 
slight septal uptake. Anx A5 imaging in DCM patients may be used to 
monitor the development of DCM.
C: Cardiac tumor imaging - Images 
show an area of enhanced 99mTc-Annexin A5, 
which is localized in the cardiac region, as 
indicated by 201Tl perfusion scintigraphy, 
resembling the echocardiographic image of 
the tumor(11). This noninvasive tool may 
differentiate between benign and malignant 
lesions and could help improve the treatment 



















calcifi ed nodules (3-7%)(35-38). The ruptured plaque is characterized by a 
lesion with a necrotic core, with an overlying thin ruptured fi brous cap 
that results in obstruction of the coronary artery. The eroded plaque 
has a thrombus which adheres to a proteoglycan-rich layer and smooth 
muscle cells with minimal infl ammation. Lastly, the calcifi ed nodule is the 
least common of all lesions that cause thrombosis. It shows a calcifi ed 
plate with superimposed bony nodules that result in discontinuity of 
the fi brous cap without endothelial cells with overlying luminal 
thrombus.
The knowledge that a large fraction of ruptured plaques have non-
signifi cant stenoses warrant the move beyond stress testing and 
coronary angiography in order to attempt identifi cation of high 
risk patients with potentially vulnerable plaques that are not fl ow-
limiting(39-41). Multi-slice computed tomography (MSCT) is one of the 
important candidates for detection of atherosclerotic lesions in the 
coronary artery wall following an intravenous injection of a contrast 
agent(42). MSCT technology has dramatically increased the ability to 
detect coronary artery plaque noninvasively in patients at risk, detecting 
both soft and calcifi ed plaques for imaging. However, the ability to 
identify the biological characteristic of high risk plaques using MSCT 
remains limited. Therefore, the challenge remains to fi nd a method 
that detects the potentially lethal plaque. To achieve this, quantifi able 
information regarding the cellular, biochemical and molecular 
composition of lesions needs to be obtained. Various imaging techniques, 
such as angioscopy(43) and intravascular ultrasonography(44, 45) or more 
recently with optical coherence tomography,(46, 47) thermography,(48, 49) 
elastography(50, 51) and magnetic resonance imaging,(52) have attempted 
to characterize these plaques using tissue characteristics such as fi brous 
cap thickness, necrotic core and the severity of the infl ammatory 
component in the lesions. Although promising, these technologies have 
shown limited clinical success.
To collect information about the molecular and cellular composition of 
plaques, PET and SPECT nuclear imaging have emerged as potential 
tools to fi nd a plaque vulnerable to rupture. Potential targets for the 
detection of infl ammation in vulnerable plaque are LDL and macrophage 
content(53). Although the application of nuclear imaging to characterize 
atherosclerotic lesions is still in its infancy, one of the fi rst promising 
attempts was imaging the unstable plaque using 99mTc-Anx A5(54). In a 
preliminary study, 4 patients were imaged with carotid vascular disease, 
2 of whom had suffered a recent transient ischemic attack (TIA). Anx 
A5 uptake was seen in the carotid region in the two patients, with 
recent TIA. No uptake was discernable in the other two patients who 
were being treated with statins after suffering a TIA longer than six 
months prior to imaging (Figure 4A). One day after Anx A5 SPECT 
imaging, patients underwent carotid endarterectomy. Positive images 
correlated with plaque macrophage content and Anx A5 uptake, 
whereas both patients with negative annexin scans had smooth muscle 
cell-rich lesions. One of the two positive patients with recent TIA had a 
large atheroma in the contralateral carotid artery, however without 
Anx A5 uptake. These data indicate a promising potential for Anx A5 
imaging for the detection of the vulnerable plaque.
The fi rst studies to show that 18F-FDG might have a role in imaging 
atherosclerosis were performed in a rabbit model, showing uptake by 
macrophages in plaques in the aortic arch. 18F-FDG uptake appeared to 
be related to macrophage content of the plaque(55). Consequently, a 
clinical study using FDG-PET imaging was performed by Rudd et al.(56), 
where FDG-PET scans were performed on 8 patients who had suffered 
a recent TIA and in whom there was evidence of internal carotid artery 
stenosis. Co-registration with CT angiograms confi rmed signifi cant FDG 
uptake coinciding with identifi ed stenotic plaques. In the contralateral 
asymptomatic plaques, signifi cantly less FDG uptake was found 





In another study by Dunphy et al. patients with suspected cancer were 
scanned by CT and FDG-PET (Figure 4C)(57). Atherosclerotic coronary 
arteries were found in a subset of these patients. FDG uptake was 
found in the coronary artery with a proximal and multifocal pattern, 
which agreed with autopsy fi ndings. One limitation of coronary 
18F-FDG imaging was refl ected by the fact that myocardial and hepatic 
FDG uptake prevented evaluation in coronary arteries in approximately 
half of the patients. The use of beta-blockers prior to imaging may be 
necessary to suppress this uptake in the myocardium.
The abovementioned glucose metabolism imaging studies provide 
proof of the principle that FDG-PET can image atherosclerotic plaque 
infl ammation and is able to quantify plaque infl ammatory cell activity. If 
confi rmed, these observations suggest that FDG-PET could be used to 
identify potentially unstable plaques and to monitor effects of drug 
therapy on plaque infl ammation. 
OUTLOOK                                                                            
Almost one-third of total global deaths are caused by the various forms 
of cardiovascular disease. Around 80% of these deaths take place in low 
and middle-income countries. Consequently, cardiovascular disease is 
estimated to be the leading cause of death in developing countries by 
2010. Until recently, the diagnosis of cardiovascular disease has been 
principally focused on the early detection of anatomical and mechanical 
changes. However, molecular imaging techniques have advanced to the 
detection of early and pre-disease molecular and cellular changes and 
may prove useful for early diagnosis in such a way that events can be 
reduced or disease can even be prevented. 
Another opportunity for molecular imaging lies in clinical trials for the 
evaluation of new drugs. By using a molecular imaging approach, a 
reduction in the number of patients is needed for a trial, since molecular 
imaging could be able to identify a high-risk subgroup in which most 
events would be expected to occur. 
A: Imaging unstable plaque lesions of the carotid artery using 
99mTc-Annexin A5. Panel A (upper) shows images obtained by 
SPECT in patient 1, who experienced a left-sided TIA 3 days 
before imaging. This patient had signifi cant stenoses of both 
carotid arteries. Only one side showed uptake of 99mTc-
Annexin A5, which coincided with the culprit lesion (see 
arrows). Histopathology of the plaque performed after 
endarterectomy showed substantial infi ltration of macrophages 
into the neointima, with extensive binding of annexin A5 (anti-
Annexin A5 antibody, brown). Lower panel shows Anx A5 
imaging in a second patient, who had experienced a right-
sided TIA three months before, did not show uptake in the 
carotid region, neither left or right. Histologic analysis showed 
a lesion rich in smooth-muscle cells, with negligible binding of 
Annexin A5. This preliminary study suggests that Anx A5 may 
provide a valuable tool in assessing plaque vulnerability. 
Modifi ed from original fi gure by Kietselaer et al. NEJM 2004(54).
 FIGURE 4: Unstable Plaque imaging
B: FDG-PET (left), CT angiography (middle) and fused 
(right) images from a patient with carotid stenosis who was 
symptomatic (top row) and with a contralateral asymptomatic 
carotid stenosis (bottom row). The arrows point at FDG 
uptake corresponding to stenotic carotid plaque. Note that 
FDG uptake into symptomatic plaque was signifi cantly 
higher. Modifi ed with permission from original fi gure by Rudd 
et al. Circulation 2002(56). 
C: PET / CT images show transaxial slices through heart. 
Enhanced uptake of FDG, refl ecting infl ammation (arrow-
heads), is present proximal and distal to the calcifi ed left 
anterior descending artery (arrow).  A tumor is localized 
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